Skip to main content
Top
Published in: Advances in Therapy 6/2024

Open Access 25-04-2024 | Coronary Heart Disease | Original Research

The Use of Precision Epigenetic Methods for the Diagnosis and Care of Stable Coronary Heart Disease Reduces Healthcare Costs

Authors: David Frisvold, Meeshanthini Dogan, Timur Dogan, Khullani Abdullahi, Tyler Koep, Robert Philibert

Published in: Advances in Therapy | Issue 6/2024

Login to get access

Abstract

Introduction

The cost of secondary prevention of coronary heart disease (CHD) is continuing to increase, with a substantial portion of this acceleration being driven by the expense of confirmatory diagnostic testing. Conceivably, newly developed precision epigenetic technologies could drive down these costs. However, at the current time, their impact on overall expense for CHD care is poorly understood. We hypothesized that the use of a newly developed, highly sensitive, and specific epigenetic test, PrecisionCHD, could decrease the costs of secondary prevention.

Methods

To test this hypothesis, we constructed a budget impact analysis using a cost calculation model that examined the effects of substituting PrecisionCHD for conventional CHD diagnostic tests on the expenses of the initial evaluation and first year of care of stable CHD using a 1-year time horizon with no discounting.

Results

The model projected that for a commercial insurer with one million members, full adoption of PrecisionCHD as the primary method of initial CHD assessment would save approximately $113.6 million dollars in the initial year.

Conclusion

These analyses support the use of precision epigenetic methods as part of the initial diagnosis and care of stable CHD and can meaningfully reduce cost. Real-world pilots to test the reliability of these analyses are indicated.
Appendix
Available only for authorised users
Literature
1.
go back to reference Finegold JA, Asaria P, Francis DP. Mortality from ischaemic heart disease by country, region, and age: statistics from World Health Organisation and United Nations. Int J Cardiol. 2013;168(2):934–45.CrossRefPubMedPubMedCentral Finegold JA, Asaria P, Francis DP. Mortality from ischaemic heart disease by country, region, and age: statistics from World Health Organisation and United Nations. Int J Cardiol. 2013;168(2):934–45.CrossRefPubMedPubMedCentral
2.
go back to reference Benjamin EJ, Virani SS, Callaway CW, et al. Heart disease and stroke statistics—2018 update: a report from the American Heart Association. Circulation. 2018;137(12):e67–492.CrossRefPubMed Benjamin EJ, Virani SS, Callaway CW, et al. Heart disease and stroke statistics—2018 update: a report from the American Heart Association. Circulation. 2018;137(12):e67–492.CrossRefPubMed
3.
go back to reference Goff DC, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk. Circulation. 2014;129(25_suppl_2):S49–S73.CrossRefPubMed Goff DC, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk. Circulation. 2014;129(25_suppl_2):S49–S73.CrossRefPubMed
4.
go back to reference Virani SS, Alonso A, Benjamin EJ, et al. Heart disease and stroke statistics—2020 update: a report from the American Heart Association. Circulation. 2020;141(9):e139–596.CrossRefPubMed Virani SS, Alonso A, Benjamin EJ, et al. Heart disease and stroke statistics—2020 update: a report from the American Heart Association. Circulation. 2020;141(9):e139–596.CrossRefPubMed
5.
go back to reference Reed SC, Dhir N, Widmer RJ. Optimal cardiovascular medical therapy: current guidelines and new developments. Proc (Bayl Univ Med Cent). 2022;35(5):636–42. Reed SC, Dhir N, Widmer RJ. Optimal cardiovascular medical therapy: current guidelines and new developments. Proc (Bayl Univ Med Cent). 2022;35(5):636–42.
6.
go back to reference Boden WE, O’Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356(15):1503–16.CrossRefPubMed Boden WE, O’Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356(15):1503–16.CrossRefPubMed
7.
go back to reference Maron DJ, Hochman JS, Reynolds HR, et al. Initial invasive or conservative strategy for stable coronary disease. N Engl J Med. 2020;382(15):1395–407.CrossRefPubMedPubMedCentral Maron DJ, Hochman JS, Reynolds HR, et al. Initial invasive or conservative strategy for stable coronary disease. N Engl J Med. 2020;382(15):1395–407.CrossRefPubMedPubMedCentral
8.
go back to reference Joseph J, Velasco A, Hage FG, Reyes E. Guidelines in review: comparison of ESC and ACC/AHA guidelines for the diagnosis and management of patients with stable coronary artery disease. J Nucl Cardiol. 2018;25(2):509–15.CrossRefPubMed Joseph J, Velasco A, Hage FG, Reyes E. Guidelines in review: comparison of ESC and ACC/AHA guidelines for the diagnosis and management of patients with stable coronary artery disease. J Nucl Cardiol. 2018;25(2):509–15.CrossRefPubMed
10.
go back to reference James MT, Samuel SM, Manning MA, Tonelli M, Ghali WA, Faris P, et al. Contrast-induced acute kidney injury and risk of adverse clinical outcomes after coronary angiography. Circulation: Cardiovascular Interventions. 2013;6(1):37–43.PubMed James MT, Samuel SM, Manning MA, Tonelli M, Ghali WA, Faris P, et al. Contrast-induced acute kidney injury and risk of adverse clinical outcomes after coronary angiography. Circulation: Cardiovascular Interventions. 2013;6(1):37–43.PubMed
11.
go back to reference Azzalini L, Candilio L, McCullough PA, Colombo A. Current risk of contrast-induced acute kidney injury after coronary angiography and intervention: a reappraisal of the literature. Can J Cardiol. 2017;33(10):1225–8.CrossRefPubMed Azzalini L, Candilio L, McCullough PA, Colombo A. Current risk of contrast-induced acute kidney injury after coronary angiography and intervention: a reappraisal of the literature. Can J Cardiol. 2017;33(10):1225–8.CrossRefPubMed
12.
go back to reference Hausleiter J, Meyer T, Hermann F, et al. Estimated radiation dose associated with cardiac CT angiography. JAMA. 2009;301(5):500–7.CrossRefPubMed Hausleiter J, Meyer T, Hermann F, et al. Estimated radiation dose associated with cardiac CT angiography. JAMA. 2009;301(5):500–7.CrossRefPubMed
13.
go back to reference Ma X, Mo C, Li Y, Chen X, Gui C. Prediction of the development of contrast-induced nephropathy following percutaneous coronary artery intervention by machine learning. Acta Cardiologica. 2023;78:1–10.CrossRef Ma X, Mo C, Li Y, Chen X, Gui C. Prediction of the development of contrast-induced nephropathy following percutaneous coronary artery intervention by machine learning. Acta Cardiologica. 2023;78:1–10.CrossRef
14.
go back to reference de Oliveira Laterza Ribeiro M, Correia VM, Herling de Oliveira LL, Soares PR, Scudeler TL. Evolving diagnostic and management advances in coronary heart disease. Life. 2023;13(4):951. de Oliveira Laterza Ribeiro M, Correia VM, Herling de Oliveira LL, Soares PR, Scudeler TL. Evolving diagnostic and management advances in coronary heart disease. Life. 2023;13(4):951.
15.
go back to reference Xia Y, Brewer A, Bell JT. DNA methylation signatures of incident coronary heart disease: findings from epigenome-wide association studies. Clin Epigenet. 2021;13(1):1–16.CrossRef Xia Y, Brewer A, Bell JT. DNA methylation signatures of incident coronary heart disease: findings from epigenome-wide association studies. Clin Epigenet. 2021;13(1):1–16.CrossRef
16.
go back to reference Philibert R, Dogan TK, Knight S, et al. Validation of an integrated genetic-epigenetic test for the assessment of coronary heart disease. J Am Heart Assoc. 2023;12:e030934.CrossRefPubMedPubMedCentral Philibert R, Dogan TK, Knight S, et al. Validation of an integrated genetic-epigenetic test for the assessment of coronary heart disease. J Am Heart Assoc. 2023;12:e030934.CrossRefPubMedPubMedCentral
17.
go back to reference Philibert R, Moody J, Philibert W, Dogan MV, Hoffman EA. The reversion of the epigenetic signature of coronary heart disease in response to smoking cessation. Genes. 2023;14(6):1233.CrossRefPubMedPubMedCentral Philibert R, Moody J, Philibert W, Dogan MV, Hoffman EA. The reversion of the epigenetic signature of coronary heart disease in response to smoking cessation. Genes. 2023;14(6):1233.CrossRefPubMedPubMedCentral
18.
go back to reference Zhang X, Wang C, He D, et al. Identification of DNA methylation-regulated genes as potential biomarkers for coronary heart disease via machine learning in the Framingham Heart Study. Clin Epigenet. 2022;14(1):1–17.CrossRef Zhang X, Wang C, He D, et al. Identification of DNA methylation-regulated genes as potential biomarkers for coronary heart disease via machine learning in the Framingham Heart Study. Clin Epigenet. 2022;14(1):1–17.CrossRef
20.
go back to reference Postma MJ. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Conference. Expert Rev Pharmacoecon Outcomes Res. 2009;9(4):305–7.CrossRefPubMed Postma MJ. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Conference. Expert Rev Pharmacoecon Outcomes Res. 2009;9(4):305–7.CrossRefPubMed
21.
go back to reference Sarpong EM, Zuvekas SH. Statistical brief# 458 Trends in Statin Therapy among Adults (Age≥ 18), United States, 2000 to 2011. Rockville (MD): Agency for Healthcare Research and Quality (US). Sarpong EM, Zuvekas SH. Statistical brief# 458 Trends in Statin Therapy among Adults (Age≥ 18), United States, 2000 to 2011. Rockville (MD): Agency for Healthcare Research and Quality (US).
24.
go back to reference Hwang D, Park S-H, Koo B-K. Ischemia with nonobstructive coronary artery disease: concept, assessment, and management. JACC Asia. 2023;3(2):169–84. Hwang D, Park S-H, Koo B-K. Ischemia with nonobstructive coronary artery disease: concept, assessment, and management. JACC Asia. 2023;3(2):169–84.
25.
go back to reference Asch DA, Troxel AB, Stewart WF, et al. Effect of financial incentives to physicians, patients, or both on lipid levels: a randomized clinical trial. JAMA. 2015;314(18):1926–35.CrossRefPubMedPubMedCentral Asch DA, Troxel AB, Stewart WF, et al. Effect of financial incentives to physicians, patients, or both on lipid levels: a randomized clinical trial. JAMA. 2015;314(18):1926–35.CrossRefPubMedPubMedCentral
26.
go back to reference Tecson KM, Kluger AY, Cassidy-Bushrow AE, et al. Usefulness of statins as secondary prevention against recurrent and terminal major adverse cardiovascular events. Am J Cardiol. 2022;176:37–42.CrossRefPubMed Tecson KM, Kluger AY, Cassidy-Bushrow AE, et al. Usefulness of statins as secondary prevention against recurrent and terminal major adverse cardiovascular events. Am J Cardiol. 2022;176:37–42.CrossRefPubMed
27.
go back to reference Morrow D, De Lemos J. Stable ischemic heart disease. Braunwald’s heart disease: a textbook of cardiovascular medicine. 12th. Philadelphia: Elsevier; 2022. Morrow D, De Lemos J. Stable ischemic heart disease. Braunwald’s heart disease: a textbook of cardiovascular medicine. 12th. Philadelphia: Elsevier; 2022.
28.
go back to reference Subramanian S, Tumlin J, Bapat B, Zyczynski T. Economic burden of contrast-induced nephropathy: implications for prevention strategies. J Med Econ. 2007;10(2):119–34.CrossRefPubMed Subramanian S, Tumlin J, Bapat B, Zyczynski T. Economic burden of contrast-induced nephropathy: implications for prevention strategies. J Med Econ. 2007;10(2):119–34.CrossRefPubMed
30.
go back to reference Herscovici R, Sedlak T, Wei J, Pepine CJ, Handberg E, Merz CNB. Ischemia and no obstructive coronary artery disease (INOCA): what is the risk? J Am Heart Assoc. 2018;7(17): e008868.CrossRefPubMedPubMedCentral Herscovici R, Sedlak T, Wei J, Pepine CJ, Handberg E, Merz CNB. Ischemia and no obstructive coronary artery disease (INOCA): what is the risk? J Am Heart Assoc. 2018;7(17): e008868.CrossRefPubMedPubMedCentral
31.
go back to reference Clebak KT, Nickolich S, Mendez-Miller M. Multitarget stool DNA testing (Cologuard) for colorectal cancer screening. Am Fam Physician. 2022;105(2):198–200.PubMed Clebak KT, Nickolich S, Mendez-Miller M. Multitarget stool DNA testing (Cologuard) for colorectal cancer screening. Am Fam Physician. 2022;105(2):198–200.PubMed
33.
go back to reference Mehdi A, Taliercio JJ, Nakhoul G. Contrast media in patients with kidney disease: an update. Clevel Clin J Med. 2020;87(11):683–94.CrossRef Mehdi A, Taliercio JJ, Nakhoul G. Contrast media in patients with kidney disease: an update. Clevel Clin J Med. 2020;87(11):683–94.CrossRef
34.
go back to reference Martin AR, Kanai M, Kamatani Y, Okada Y, Neale BM, Daly MJ. Clinical use of current polygenic risk scores may exacerbate health disparities. Nat Genet. 2019;51(4):584.CrossRefPubMedPubMedCentral Martin AR, Kanai M, Kamatani Y, Okada Y, Neale BM, Daly MJ. Clinical use of current polygenic risk scores may exacerbate health disparities. Nat Genet. 2019;51(4):584.CrossRefPubMedPubMedCentral
37.
go back to reference Dogan MV, Xiang J, Beach SR, et al. Ethnicity and smoking-associated DNA methylation changes at HIV co-receptor GPR15. Front Psych. 2015;6:132. Dogan MV, Xiang J, Beach SR, et al. Ethnicity and smoking-associated DNA methylation changes at HIV co-receptor GPR15. Front Psych. 2015;6:132.
39.
40.
41.
go back to reference Dash S, Shakyawar SK, Sharma M, Kaushik S. Big data in healthcare: management, analysis and future prospects. J Big Data. 2019;6(1):54.CrossRef Dash S, Shakyawar SK, Sharma M, Kaushik S. Big data in healthcare: management, analysis and future prospects. J Big Data. 2019;6(1):54.CrossRef
Metadata
Title
The Use of Precision Epigenetic Methods for the Diagnosis and Care of Stable Coronary Heart Disease Reduces Healthcare Costs
Authors
David Frisvold
Meeshanthini Dogan
Timur Dogan
Khullani Abdullahi
Tyler Koep
Robert Philibert
Publication date
25-04-2024
Publisher
Springer Healthcare
Published in
Advances in Therapy / Issue 6/2024
Print ISSN: 0741-238X
Electronic ISSN: 1865-8652
DOI
https://doi.org/10.1007/s12325-024-02860-7

Other articles of this Issue 6/2024

Advances in Therapy 6/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Webinar | 06-02-2024 | 20:00 (CET)

Mastering chronic pancreatitis pain: A multidisciplinary approach and practical solutions

Severe pain is the most common symptom of chronic pancreatitis. In this webinar, experts share the latest insights in pain management for chronic pancreatitis patients. Experts from a range of disciplines discuss pertinent cases and provide practical suggestions for use within clinical practice.

Sponsored by: Viatris

Developed by: Springer Healthcare